Marketed Indications

XIAFLEX is currently marketed in the U.S. by our partner Endo Pharmaceuticals for Dupuytren’s contracture and Peyronie’s disease. XIAFLEX® is the first and only FDA-approved nonsurgical treatment for these two indications. For full prescribing information, please visit www.xiaflex.com.

Cellulite